BofA Securities Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Announces Target Price $27
The Latest Analyst Ratings For Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Analyst Ratings
Truist Adjusts Price Target on Catalyst Pharmaceuticals to $30 From $25, Maintains Buy Rating
Catalyst Pharmaceuticals Analyst Ratings
Catalyst Pharmaceuticals Analyst Ratings
Catalyst Pharmaceuticals Analyst Ratings
Catalyst Pharmaceuticals Analyst Ratings
Catalyst Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $34 Price Target
Catalyst Pharmaceuticals Analyst Ratings
Catalyst Pharmaceuticals Analyst Ratings
BofA Securities Initiates Catalyst Pharmaceuticals With Buy Rating, Price Target Is $23
Catalyst Pharmaceuticals Analyst Ratings
Catalyst Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $27 Price Target
Catalyst Pharmaceuticals Analyst Ratings
Catalyst Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Catalyst Pharmaceuticals, Maintains $24 Price Target
Catalyst Pharmaceuticals Analyst Ratings